Document is current

Article History

Received: 17 August 2023

Accepted: 4 December 2023

First Online: 15 December 2023

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The trial and cost-effectiveness analysis were approved by the Human Research Ethics Committee of Melbourne Health (HREC/17/MH/106) and registered with ClinicalTrials.gov, (NCT03429387).

: All authors have read and approved the submission and publication of the manuscript.

: MAS has been on data safety monitoring and adjudication committees for Cidara, Roche and Pfizer. She has received research funding from Gilead Sciences, Merck, F2G and sat on advisory boards for Gilead Sciences, F2G, Cidara, Takeda and Merck. RJH is a shareholder in Telix Pharmaceuticals and Founder of PreMIT Pty Ltd, a research and development company investigating novel PET agents. AD has received a research grant and honoraria paid to her institution from Gilead Sciences. SYT has received a research grant from Gilead Sciences. JS has received honoraria and has served as a speaker and advisory board member for Alexion, Sobi, Takeda, Eli Lilly, Novartis, BioCryst, Samsung Bioepis and Link Pharmaceuticals. SH has received research grants from Janssen Cilag, Amgen, Celgene, GSK, Novartis and Haemalogix, and honoraria from Celgene, Janseen, Novartis, Kite/Gilead, CSL Bering. He is a consultant and on the advisory board of AbbVie, Celgene, GSK, Janssen Cilag, Novartis, Roche/Genetec and Takeda. He is a consultant for Haemalogix, Sanofi, Eusa and Teruno.